GB Sciences Financials
This page shows GB Sciences (GBLX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
GB Sciences passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, GB Sciences generates $0.72 in operating cash flow (-$976K OCF vs -$1.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
GB Sciences earns $-6.5 in operating income for every $1 of interest expense (-$1.4M vs $219K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
GB Sciences generated $0 in revenue in fiscal year 2024.
GB Sciences's EBITDA was -$1.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 11.8% from the prior year.
GB Sciences reported -$1.4M in net income in fiscal year 2024. This represents an increase of 67.0% from the prior year.
GB Sciences held $12K in cash against $0 in long-term debt as of fiscal year 2024.
GB Sciences had 406M shares outstanding in fiscal year 2024. This represents an increase of 6.3% from the prior year.
GB Sciences invested $262K in research and development in fiscal year 2024. This represents a decrease of 46.7% from the prior year.
GBLX Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q1'24 | Q1'23 | Q3'24 | Q2'24 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $97K | $0 | $0 | N/A | $0 | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 | N/A | $0 | $0 | $0 | $0 |
| Gross Profit | $97K | $0 | $0 | N/A | $0 | $0 | $0 | $0 |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $164K+3.8% | $158K-37.9% | $254K | N/A | $460K+12.8% | $407K+47.7% | $276K-44.1% | $493K |
| Operating Income | -$67K+57.8% | -$158K+37.9% | -$254K | N/A | -$460K-12.8% | -$407K-47.7% | -$276K+44.1% | -$493K |
| Interest Expense | $34K+3.1% | $33K+6.0% | $31K | N/A | $39K-7.0% | $41K+11.4% | $37K-43.0% | $65K |
| Income Tax | $0 | $0 | $0 | N/A | $0 | $0 | $0 | $0 |
| Net Income | -$100K+47.3% | -$191K+33.2% | -$285K | N/A | -$498K-11.0% | -$449K-43.4% | -$313K+50.5% | -$632K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | $0.00 | N/A | N/A |
GBLX Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q1'24 | Q1'23 | Q3'24 | Q2'24 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $94K+0.7% | $94K+2.5% | $91K-11.6% | $103K-70.6% | $352K0.0% | $352K-88.7% | $3.1M+22.3% | $2.5M |
| Current Assets | $94K+0.7% | $94K+2.5% | $91K-11.6% | $103K-66.6% | $310K0.0% | $310K-64.8% | $878K+168.0% | $328K |
| Cash & Equivalents | $3K+30.0% | $2K | $0-100.0% | $12K-89.1% | $110K0.0% | $110K-83.3% | $658K+181.2% | $234K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $1.5M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $193K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $6.0M+1.7% | $5.9M+3.4% | $5.7M+4.9% | $5.4M+13.8% | $4.8M0.0% | $4.8M+10.4% | $4.3M-0.5% | $4.3M |
| Current Liabilities | $5.4M-0.4% | $5.4M+1.5% | $5.4M+5.2% | $5.1M+7.1% | $4.8M0.0% | $4.8M+16.3% | $4.1M+4.0% | $3.9M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$5.9M-1.7% | -$5.8M-3.4% | -$5.6M-5.2% | -$5.3M-20.6% | -$4.4M0.0% | -$4.4M-269.3% | -$1.2M+33.1% | -$1.8M |
| Retained Earnings | -$110.6M-0.1% | -$110.5M-0.2% | -$110.4M-0.3% | -$110.1M-1.3% | -$108.7M0.0% | -$108.7M-3.1% | -$105.4M-0.8% | -$104.6M |
GBLX Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q1'24 | Q1'23 | Q3'24 | Q2'24 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$124K-15.4% | -$108K-389.7% | -$22K+91.3% | -$252K-14.8% | -$220K+44.9% | -$399K+35.1% | -$616K+7.5% | -$665K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0 | N/A | N/A | $0 | $0+100.0% | -$1K+95.6% | -$30K+69.7% | -$100K |
| Financing Cash Flow | $125K+13.6% | $110K+1000.0% | $10K-96.0% | $247K+342.9% | $56K+227.6% | $17K-98.6% | $1.2M+347.4% | -$505K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
GBLX Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q1'24 | Q1'23 | Q3'24 | Q2'24 | Q1'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -68.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -103.2% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -106.2%+97.0pp | -203.2%+108.5pp | -311.7% | N/A | -21.3%+106.1pp | -127.4%-117.3pp | -10.0%-3.9pp | -6.1% |
| Current Ratio | 0.020.0 | 0.020.0 | 0.020.0 | 0.02-0.0 | 0.070.0 | 0.07-0.1 | 0.21+0.1 | 0.08 |
| Debt-to-Equity | -1.020.0 | -1.020.0 | -1.020.0 | -1.02+0.1 | -1.080.0 | -1.08+2.5 | -3.61-1.2 | -2.43 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$5.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.02), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is GB Sciences's annual revenue?
GB Sciences (GBLX) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is GB Sciences profitable?
No, GB Sciences (GBLX) reported a net income of -$1.4M in fiscal year 2024.
What is GB Sciences's EBITDA?
GB Sciences (GBLX) had EBITDA of -$1.4M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is GB Sciences's operating cash flow?
GB Sciences (GBLX) generated -$976K in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are GB Sciences's total assets?
GB Sciences (GBLX) had $103K in total assets as of fiscal year 2024, including both current and long-term assets.
How much does GB Sciences spend on research and development?
GB Sciences (GBLX) invested $262K in research and development during fiscal year 2024.
How many shares does GB Sciences have outstanding?
GB Sciences (GBLX) had 406M shares outstanding as of fiscal year 2024.
What is GB Sciences's current ratio?
GB Sciences (GBLX) had a current ratio of 0.02 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is GB Sciences's debt-to-equity ratio?
GB Sciences (GBLX) had a debt-to-equity ratio of -1.02 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is GB Sciences's return on assets (ROA)?
GB Sciences (GBLX) had a return on assets of -1316.4% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is GB Sciences's cash runway?
Based on fiscal year 2024 data, GB Sciences (GBLX) had $12K in cash against an annual operating cash burn of $976K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is GB Sciences's debt-to-equity ratio negative or unusual?
GB Sciences (GBLX) has negative shareholder equity of -$5.3M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is GB Sciences's Piotroski F-Score?
GB Sciences (GBLX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GB Sciences's earnings high quality?
GB Sciences (GBLX) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can GB Sciences cover its interest payments?
GB Sciences (GBLX) has an interest coverage ratio of -6.5x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.